Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
about
Obesity and cancer: mechanistic insights from transdisciplinary studiesMetformin as an adjuvant treatment for cancer: a systematic review and meta-analysisDissecting the Dual Role of AMPK in Cancer: From Experimental to Human StudiesNutrition, dietary interventions and prostate cancer: the latest evidenceEffect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studiesMetformin effects on biochemical recurrence and metabolic signaling in the prostate.Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH databaseInvolvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapyIs clinical stage T2c prostate cancer an intermediate- or high-risk disease?Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.Predicting bone scan positivity in non-metastatic castration-resistant prostate cancerMetformin use and risk of prostate cancer: results from the REDUCE study.Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature.Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.Tumor features and survival after radical prostatectomy among antidiabetic drug users.Metformin and prostate cancer mortality: a meta-analysis.Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
P2860
Q26786829-89819A90-3E60-4953-A67B-4D9A917638EEQ28074225-01C788F8-40CA-43DD-AAC8-0B895095C3FCQ28081491-493C9C02-848F-4BBE-B0BB-101F357E136EQ28084566-5A241BFD-C773-4FDD-ACA5-FBD5F66865E6Q28542914-793A2740-EC86-49EA-BAE5-E846CA2645A6Q30665188-621A27D9-0034-4AFD-AAC0-7E430CA52463Q34458822-46BD8AAC-1D02-44A0-9EB5-56275D4BB81AQ35149589-77B67FE0-D089-46CA-9D90-DAC342F979B1Q35536948-E29AE319-DA14-49CF-AF1C-BCAD25F04C45Q35558619-6AB31F71-D285-4617-BCEE-06CDE50D842BQ36268971-9136F723-A7E4-40FB-B788-F3D0F329AFB3Q36296255-CA387D05-A85F-4935-8014-8BB30319E90CQ37636973-FF6F4D9E-15B7-4CE1-9125-BE7723C93EF5Q37690270-5CA5D492-C439-4D00-89F4-BBD6B6BCE938Q38226775-AF114644-FCAE-4925-A894-B4EBDFC20B7DQ38323902-346019E4-68D6-4165-B4AB-11629BC06720Q38659182-F28DB567-89EF-4D4D-982F-46DDA6556D8EQ39018266-3AC69438-20C9-4B4F-AEC8-81F3F8A19693Q39124486-2DA052B9-A25F-4187-8822-CB1AF01DAB0DQ39510855-08E2DF3B-449D-4AF4-87C2-68E2734DED88Q41149937-BF0BCCF5-8F9F-446F-94C5-8D76070468D5Q41328850-07F52E5F-04DD-47F6-9F5F-D3F297C07B9AQ41387025-33F47870-15B2-46A1-A102-1B632F9E5CD8Q41717903-5413B047-3ACC-4430-AD9B-0FBB0E27B31AQ41718014-73D9BFE4-481F-419F-8ED2-18CAD5414D1DQ41964435-4C71D58A-5AD1-4AC6-91B6-A97207A4FED5Q42646205-6153AF98-6A5A-4330-BDC7-1932601E761DQ50792392-EB846F83-CCD5-41BA-BBE1-4DF5327F67CAQ53166209-C070C5E2-C2D2-410A-9084-DC7212FCF463
P2860
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metformin does not affect risk ...... ults from the SEARCH database.
@en
Metformin does not affect risk ...... ults from the SEARCH database.
@nl
type
label
Metformin does not affect risk ...... ults from the SEARCH database.
@en
Metformin does not affect risk ...... ults from the SEARCH database.
@nl
prefLabel
Metformin does not affect risk ...... ults from the SEARCH database.
@en
Metformin does not affect risk ...... ults from the SEARCH database.
@nl
P2093
P2860
P356
P1476
Metformin does not affect risk ...... sults from the SEARCH database
@en
P2093
C L Amling
E H Allott
P G Moorman
S J Freedland
W J Aronson
P2860
P2888
P304
P356
10.1038/PCAN.2013.48
P577
2013-10-08T00:00:00Z